New developments in non-alcoholic fatty hepatitis (NASH): Lanifibranor reaches key end point in mid-term study

With obesity and its relatedmetabolic syndromethe epidemic trend of globalization, non-alcoholic fatty liver disease has now become an important cause of chronic liver disease in developed countries such as Europe and the United States and rich areas of ChinaThe pharmaceutical company Inventiva reported that in a phase IIb trial, the experimental drug lanifibranor treated non-alcoholic fatty hepatitis (NASH) reached the primary endpoint and the primary secondary endpointBased on the data, the company said it plans to promote the small molecule pan-PPAR agonis lanifibranor into Stage III clinicalResults from the IIb trial (NATIVE study) showed that patients receiving high doses of lanifibranor had at least two points lower in their fat denatured fibrosis (SAF) scores than baselinesSpecifically, 49 percent of patients in the lanifibranor high-dose group achieved the primary endpoint, compared with 27 percent in the placebo groupThe company added that both doses of lanifibranor reached the primary secondary endpoint and did not worsen fibrosisPierre Broqua, Chief Scientific Officer at Inventiva, said: "Given that this is a global trial, lanifibranor met both theFDAand EMA regulatory targets in just six months of treatmentWe are therefore optimistic about the potential of the candidate drug lanifibranor in Key Phase III clinical trials."